Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Di Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-2779-8589; OpenAlex author ID A5115595798. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 17

  1. CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. First author DOI 10.1002/ctm2.70501↗
  2. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-023-09679-w↗
  3. LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer. First author DOI 10.1007/s12672-022-00522-0↗
  4. WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressiveness. Co-author DOI 10.1038/s41416-020-0929-0↗
  5. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/1533034617748429↗
  6. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Co-author DOI 10.2147/ijn.s166769↗
  7. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival. Co-author DOI 10.1016/s1499-3872(16)60168-6↗
  8. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. Co-author DOI 10.2147/ijn.s131295↗
  9. Application of Deuteporfin in the Metastatic Lymph Node Mapping of Pancreatic Cancer: An in vivo Study. Co-author DOI 10.1111/php.12574↗
  10. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Last author DOI 10.2147/ijn.s93835↗
  11. Magnetic graphene-based nanotheranostic agent for dual-modality mapping guided photothermal therapy in regional lymph nodal metastasis of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.07.064↗
  12. FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis. Co-author DOI 10.1371/journal.pone.0106741↗
  13. MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Co-author DOI 10.4161/cbt.29706↗
  14. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Co-author DOI 10.1007/s12032-013-0700-y↗
  15. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. First author DOI 10.3892/or.2013.2516↗
  16. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Co-author DOI 10.1016/j.ctrv.2012.02.003↗
  17. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Co-author DOI 10.1016/j.ctrv.2011.01.006↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jin · 11 shared papers, 2013–2020 · strength 0.68
  2. Deliang Fu · 9 shared papers, 2011–2020 · strength 0.49
  3. Lie Yao · 6 shared papers, 2013–2020 · strength 0.41
  4. Feng Yang · 8 shared papers, 2012–2018 · strength 0.39
  5. Xiaomeng He · 2 shared papers, 2022–2025 · strength 0.37
  6. Jin Wang · 2 shared papers, 2022–2025 · strength 0.37
  7. Hang He · 7 shared papers, 2013–2018 · strength 0.35
  8. Xinzhe Yu · 5 shared papers, 2015–2018 · strength 0.34
  9. Yongjian Jiang · 5 shared papers, 2013–2020 · strength 0.26
  10. Zhongyi Guo · 3 shared papers, 2017–2018 · strength 0.24
  11. Hengchao Li · 3 shared papers, 2015–2020 · strength 0.22
  12. Li Xu · 1 shared paper, 2025 · strength 0.22
  13. Jianqing Xu · 1 shared paper, 2025 · strength 0.22
  14. Wenchuan Wu · 1 shared paper, 2025 · strength 0.22
  15. Deliang Fu · 3 shared papers, 2016–2017 · strength 0.21
  16. Ji Li · 3 shared papers, 2014–2020 · strength 0.18
  17. Jichun Gu · 2 shared papers, 2017–2020 · strength 0.17
  18. Sijie Hao · 3 shared papers, 2013–2018 · strength 0.16
  19. Yanyan Kong · 1 shared paper, 2023 · strength 0.15
  20. Fang Xie · 1 shared paper, 2023 · strength 0.15
  21. Yihui Guan · 1 shared paper, 2023 · strength 0.15
  22. Yan Ma · 1 shared paper, 2022 · strength 0.15
  23. Shanshan Liu · 1 shared paper, 2022 · strength 0.15
  24. Yishen Mao · 1 shared paper, 2020 · strength 0.10
  25. Xiaohui Liu · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.